The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Open accessAbstract
Background: People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to increased urinary glucose excretion. They have been repeatedly shown to induce modest natriuresis and reduce HbA1c, blood pressure, weight, and albuminuria in patients with type 2 diabetes. However, the effects of these agents on kidney and cardiovascular events have not been extensively studied in patients with type 2 diabetes and established kidney disease. Methods: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial aims to compare the efficacy and safety of canagliflozin versus placebo at preventing clinically important kidney and cardiovascular outcomes in patients with diabetes and established kidney disease. CREDENCE is a randomized, double-blind, event-driven, placebo-controlled trial set in in 34 countries with a projected duration of ∼5.5 years and enrolling 4,401 adults with type 2 diabetes, estimated glomerular filtration rate ≥30 to <90 mL/min/1.73 m 2, and albuminuria (urinary albumin:creatinine ratio >300 to ≤5,000 mg/g). The study has 90% power to detect a 20% reduction in the risk of the primary outcome (α = 0.05), the composite of end-stage kidney disease, doubling of serum creatinine, and renal or cardiovascular death. Conclusion: CREDENCE will provide definitive evidence about the effects of canagliflozin on renal (and cardiovascular) outcomes in patients with type 2 diabetes and established kidney disease. Trial Registration: EudraCT number: 2013-004494-28; ClinicalTrials.gov identifier: NCT02065791.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An acute reduction in eGFR occurs with other classes of kidney-protective therapies, such as RAS inhibitors and SGLT2 inhibitors, and has been associated with long-term kidney protection (6,11,31,32).”
From Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“There is substantial overlap between the FLOW population and the populations studied in the dedicated kidney outcome studies with SGLT2is (CREDENCE, DAPA-CKD and EMPA-KIDNEY) [15,30,32]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Self-citationBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationVos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationWorldwide access to treatment for end-stage kidney disease: a systematic review
Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M.-H., Lv, J., Garg, A. X., Knight, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61601-9 · Cited by 2,339
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Research works printed but not linked: 1
- 3 International Diabetes Federation: IDF Diabetes Atlas, 7th edition. Brussels, Belgium, International Diabetes Federation, 2015.
Cited by
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457
Self-citation11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 398
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330
“73 m(2).(103) The trial was terminated early based on advice from the Data Monitoring Committee that pre-specified efficacy criteria had been achieved at a scheduled interim analysis.”
MethodSelf-citation11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 318
Bonnet, F., & Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.005 · Cited by 308
Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042007 · Cited by 291
Self-citation11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 289
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s011 · Cited by 275
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Desai, M., Li, Q., Deng, H., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035901 · Cited by 257
Self-citationRossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad009 · Cited by 242
“There is substantial overlap between the FLOW population and the populations studied in the dedicated kidney outcome studies with SGLT2is (CREDENCE, DAPA-CKD and EMPA-KIDNEY) [15, 30, 32], which have led to recommendations for the use of SGLT2i for patients with T2D and CKD [3].”
BackgroundSelf-citationHerrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy090 · Cited by 237
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 226
Lu, Q., Yang, L., Xiao, J.-J., Liu, Q., Ni, L., Hu, J.-W., Yu, H., Wu, X., & Zhang, B.-F. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.088 · Cited by 212
Wanner, C., Heerspink, H. J. L., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U. C., von Eynatten, M., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018010103 · Cited by 209
Self-citationSarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 204
Wheeler, D. C., Stefansson, B. V., Batiushin, M., Bilchenko, O., Cherney, D. Z. I., Chertow, G. M., Douthat, W., Dwyer, J. P., Escudero, E., Pecoits-Filho, R., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa234 · Cited by 194
Self-citationOshima, M., Neuen, B. L., Li, J., Perkovic, V., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., Mahaffey, K. W., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020050723 · Cited by 176
Self-citationSGLT2 inhibition and kidney protection
Nespoux, J., & Vallon, V. (2018) · Clinical Science · doi:10.1042/cs20171298 · Cited by 172
Jardine, M. J., Zhou, Z., Mahaffey, K. W., Oshima, M., Agarwal, R., Bakris, G., Bajaj, H. S., Bull, S., Cannon, C. P., Charytan, D. M., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019111168 · Cited by 168
Self-citationOshima, M., Jardine, M. J., Agarwal, R., Bakris, G., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.042 · Cited by 166
“(%) White 630 (66) 423 (71) 406 (69) 298 (66) 426 (66) 685 (65) Black or African American 51 (5) 28 (5) 28 (5) 21 (5) 32 (5) 54 (5) Asian 187 (20) 108 (18) 112 (19) 82 (18) 132 (20) 224 (21) Other 88 (9) 41 (7) 42 (7) 49 (11) 56 (9) 86 (8) Current smoker, no.”
Self-citationEffects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
Matthews, D. R., Li, Q., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Desai, M., Hiatt, W. R., Nehler, M. R., Fabbrini, E., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4839-8 · Cited by 143
Self-citationBakris, G., Oshima, M., Mahaffey, K. W., Agarwal, R., Cannon, C. P., Capuano, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10140620 · Cited by 142
Self-citationOshima, M., Neuen, B. L., Jardine, M. J., Bakris, G., Edwards, R., Levin, A., Mahaffey, K. W., Neal, B., Pollock, C., Rosenthal, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30300-4 · Cited by 135
Self-citationSodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
Alicic, R. Z., Neumiller, J. J., Johnson, E. J., Dieter, B. P., & Tuttle, K. R. (2019) · Diabetes · doi:10.2337/dbi18-0007 · Cited by 134
Zhou, Z., Jardine, M., Li, Q., Neuen, B. L., Cannon, C. P., de Zeeuw, D., Edwards, R., Levin, A., Mahaffey, K. W., Perkovic, V., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.031623 · Cited by 134
Self-citationNeuen, B. L., Oshima, M., Perkovic, V., Agarwal, R., Arnott, C. G., Bakris, G. L., Cannon, C. P., Charytan, D. M., Edwards, R., Górriz, J. L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab497 · Cited by 127
Self-citationEvolving spectrum of diabetic nephropathy
Kopel, J. J., Pena-Hernandez, C., & NUGENT, K. M. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i5.269 · Cited by 125
Brown, E. E., Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13650 · Cited by 117
Ye, N., Jardine, M. J., Oshima, M., Hockham, C., Heerspink, H. J. L., Agarwal, R., Bakris, G., Schutte, A. E., Arnott, C., Chang, T. I., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.048740 · Cited by 115
Self-citationSGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
Wilding, J. P. H., Fernando, K., Milne, N., Evans, M., Ali, A., Bain, S. C., Hicks, D., James, J., Newland‐Jones, P., Patel, D., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0471-8 · Cited by 113
New pharmacological strategies for protecting kidney function in type 2 diabetes
Muskiet, M. H. A., Wheeler, D. C., & Heerspink, H. J. L. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30263-8 · Cited by 113
Self-citationKelly, M. S., Lewis, J., Huntsberry, A. M., Dea, L., & Portillo, I. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2019.1549459 · Cited by 112
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 111
Ravindran, S., & Munusamy, S. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30621 · Cited by 108
The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
Newman, J. D., Vani, A. K., Alemán, J. O., WEINTRAUB, H. S., Berger, J. S., & Schwartzbard, A. Z. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.071 · Cited by 103
Rådholm, K., Wu, J. H. Y., Wong, M. G., Foote, C., Fulcher, G. R., Mahaffey, K. W., Perkovic, V., & Neal, B. C. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.027 · Cited by 101
Self-citationHeerspink, H. J. L., Apperloo, E., Davies, M., Dicker, D., Kandler, K., Rosenstock, J., Sørrig, R., Lawson, J., Zeuthen, N., & Cherney, D. (2023) · Diabetes Care · doi:10.2337/dc22-1889 · Cited by 98
Self-citationGiorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01163-9 · Cited by 95
Clinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 89
From Proteinuria to Fibrosis: An Update on Pathophysiology and Treatment Options
Sharma, S., & Smyth, B. J. (2021) · Kidney & Blood Pressure Research · doi:10.1159/000516911 · Cited by 87
Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
Dai, Z.-C., Chen, J., Zou, R., Liang, X.-B., Tang, J., & Yao, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213473 · Cited by 84
SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
Davidson, J. A. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1601404 · Cited by 82
The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients
Kukla, A., Hill, J., Merzkani, M., Bentall, A., Lorenz, E. C., Park, W. D., D’Costa, M., Kudva, Y. C., Stegall, M. D., & Shah, P. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000000971 · Cited by 73
Zhou, Z., Lindley, R. I., Rådholm, K., Jenkins, B., Watson, J., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Shaw, W., et al. (2019) · Stroke · doi:10.1161/strokeaha.118.023009 · Cited by 72
Self-citationRampersad, C., Kraut, E., Whitlock, R. H., Komenda, P. V. J., Woo, V. C., Rigatto, C., & Tangri, N. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.03.019 · Cited by 72
The Role of Deprescribing in Older Adults with Chronic Kidney Disease
Triantafylidis, L. K., Hawley, C. E., Perry, L., & Paik, J. M. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0593-8 · Cited by 70
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 69
Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives
Rossing, P. R., Persson, F., & Frimodt‐Møller, M. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.02.007 · Cited by 65
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Patti, A. M., Rizvi, A. A., Giglio, R. V., Stoian, A. P., Ligi, D., & Mannello, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040912 · Cited by 64
Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.10.003 · Cited by 63
Sodium–Glucose Cotransporter–2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes
Kramer, C. K., & Zinman, B. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-042017-094221 · Cited by 62
Self-citationSGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
Ali, A., Bain, S. C., Hicks, D., Jones, P. N., Patel, D., Evans, M., Fernando, K., James, J., Milne, N., Viljoen, A., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0657-8 · Cited by 62
Mulder, S., Hammarstedt, A., Nagaraj, S. B., Nair, V., Ju, W., Hedberg, J., Greasley, P. J., Eriksson, J. W., Oscarsson, J., & Heerspink, H. J. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14018 · Cited by 62
Self-citationSternlicht, H., & Bakris, G. L. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0920-4 · Cited by 60
Self-citationJardine, M., Zhou, Z., Heerspink, H. J. L., Hockham, C., Li, Q., Agarwal, R., Bakris, G. L., Cannon, C. P., Charytan, D. M., Greene, T., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.15260920 · Cited by 60
Self-citationCanagliflozin review – safety and efficacy profile in patients with T2DM
Jakher, H., Chang, T. I., Tan, M. J., & Mahaffey, K. W. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s184437 · Cited by 59
Self-citationUnraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells
Pirklbauer, M., Schupart, R., Fuchs, L., Staudinger, P., Corazza, U., Sallaberger, S., Leierer, J., Mayer, G. J., & Schramek, H. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00431.2018 · Cited by 57
Heerspink, H. J. L., Oshima, M., Zhang, H., Li, J., Agarwal, R., Capuano, G., Charytan, D. M., Craig, J., de Zeeuw, D., Di Tanna, G. L., et al. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.05.005 · Cited by 56
Self-citationRhee, J. J., Jardine, M., Chertow, G. M., & Mahaffey, K. W. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13987 · Cited by 55
Self-citationNangaku, M., Takama, H., Ichikawa, T., Mukai, K., Kojima, M., Suzuki, Y., Watada, H., Wada, T., Ueki, K., Narita, I., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac242 · Cited by 55
Tangri, N., Ferguson, T. W., Bamforth, R. J., Leon, S. J., Arnott, C. G., Mahaffey, K. W., Kotwal, S. S., Heerspink, H. J. L., Perkovic, V., Fletcher, R. A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15678 · Cited by 48
Self-citationThe effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial
Arnott, C. G., Huang, Y., Neuen, B. L., Tanna, G. L. D., Cannon, C. P., Oh, R., Edwards, R., Kavalam, M., Rosenthal, N. R., Perkovic, V., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14091 · Cited by 47
Self-citationPreventing and treating kidney disease in patients with type 2 diabetes
Delanaye, P., & Scheen, A. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1551362 · Cited by 47
SGLT2 inhibition to address the unmet needs in diabetic nephropathy
Barutta, F., Bernardi, S., Gargiulo, G., Durazzo, M., & Gruden, G. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3171 · Cited by 47
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
Januzzi, J. L., Mohebi, R., Liu, Y., Sattar, N. A., Heerspink, H. J. L., Tefera, E. A., Vaduganathan, M., Butler, J., Yavin, Y., Li, J., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.065251 · Cited by 46
Self-citationLamos, E. M., Hedrington, M. S., & Davis, S. N. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1626823 · Cited by 46
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Liu, B., Wang, Y., Zhang, Y., & Yan, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190828161409 · Cited by 45
Talbot, B. E. M., Fletcher, R. A., Neal, B. C., Oshima, M., Adshead, F., Moore, K., McGain, F., McAlister, S., Barraclough, K. A., Knight, J., et al. (2024) · The Lancet Planetary Health · doi:10.1016/s2542-5196(24)00281-x · Cited by 44
Self-citationChuang, A., Nguyen, M. T., Kung, W., Lehman, S. J., & Chew, D. P. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.02.17 · Cited by 44
Heo, C. U., & Choi, C. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030393 · Cited by 43
Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
Giglio, R. V., Patti, A. M., Rizvi, A. A., Stoian, A. P., Ciaccio, M., Παπάνας, Ν., Janež, A., Sönmez, A., Banach, M., Sahebkar, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020291 · Cited by 40
Sodium-glucose cotransporter inhibitors: beyond glycaemic control
Vergara, A., Jacobs-Cachá, C., & Soler, M. J. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz019 · Cited by 40
Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
Górriz, J. L., Navarro‐González, J. F., Ortíz, A., Vergara, A., Núñez, J. E., Jacobs-Cachá, C., Martínez‐Castelao, A., & Soler, M. J. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz237 · Cited by 38
Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors
Bakris, G. L. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.05.009 · Cited by 37
Self-citationBarraclough, J. Y., Yu, J., Figtree, G. A., Perkovic, V., Heerspink, H. J. L., Neuen, B. L., Cannon, C. P., Mahaffey, K. W., Schutte, A. E., Neal, B., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14671 · Cited by 37
Self-citationYi, T. W., Smyth, B. J., Tanna, G. L. D., Arnott, C. G., Cardoza, K. P., Kang, A., Pollock, C. A., Agarwal, R., Bakris, G. L., Charytan, D. M., et al. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.12.015 · Cited by 37
Self-citationType 2 diabetes and the kidney: Insights from cardiovascular outcome trials
Giugliano, D., Nicola, L. D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13743 · Cited by 37
Wanner, C., Inzucchi, S. E., Zinman, B., Koitka‐Weber, A., Mattheus, M., George, J. T., von Eynatten, M., Hauske, S. J., & EMPA‐REG OUTCOME Investigators (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14158 · Cited by 37
Self-citationBonaventura, A., Carbone, S., Dixon, D. L., Abbate, A., & Montecucco, F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12890 · Cited by 36
Scholtes, R. A., van Baar, M. J. B., Lytvyn, Y., Bjornstad, P., Nieuwdorp, M., Cherney, D. Z. I., & van Raalte, D. H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13692 · Cited by 35
Satou, R., Cypress, M. W., Woods, T. C., Katsurada, A., Dugas, C. M., Fonseca, V. A., & Navar, L. G. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00402.2019 · Cited by 34
Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice
Hudkins, K. L., Li, X., Holland, A. L., Swaminathan, S., & Alpers, C. E. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab330 · Cited by 34
Handelsman, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01054-w · Cited by 34
Weir, M. R., McCullough, P. A., Buse, J. B., & Anderson, J. E. (2020) · American Journal of Nephrology · doi:10.1159/000506533 · Cited by 32
Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
Kleinaki, Z., Kapnisi, S., Theodorelou‐Charitou, S., Nikas, I. P., & Paschou, S. Α. (2020) · HORMONES · doi:10.1007/s42000-020-00212-y · Cited by 32
Wada, T., Mori‐Anai, K., Kawaguchi, Y., Katsumata, H., Tsuda, H., Iida, M., Arakawa, K., & Jardine, M. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13624 · Cited by 32
Self-citationLi, C., Yu, J., Hockham, C., Perkovic, V., Neuen, B. L., Badve, S. V., Houston, L., Lee, V. Y., Barraclough, J., Fletcher, R. A., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14772 · Cited by 32
Self-citationSecond-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
Shin, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1171-0 · Cited by 31
SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand?
Vallianou, N. G., Tsilingiris, D., Kounatidis, D. C., Lempesis, I. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16342 · Cited by 30
A Big Win for Diabetic Kidney Disease: CREDENCE
Cherney, D. Z. I., Odutayo, A., & Verma, S. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.04.011 · Cited by 29
Metadata
- Authors
- Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., Levin, A., Pollock, C., Wheeler, D. C., Xie, J., Zhang, H., Zinman, B., Desai, M., Perkovic, V., & on behalf of the CREDENCE study investigators
- Affiliations
- The University of Sydney (AU)
- Stanford Medicine (US)
- Richard L. Roudebush VA Medical Center (US)
- University of Chicago (US)
- Brigham and Women's Hospital (US)
- Janssen Research & Development (United States) (US)
- University of Utah (US)
- University Medical Center Groningen (NL)
- University of British Columbia (CA)
- University College London (GB)
- Peking University First Hospital (CN)
- Mount Sinai Hospital (CA)
- UNSW Sydney (AU)
- ORCID
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 46
- Issue
- 6
- Pages
- 462-472
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- PMC
- PMC5804835
- OpenAlex
- W2772844083
- Cited by
- 234
- References
- 32
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 15 · 2023: 25 · 2022: 16 · 2021: 27 · 2020: 45 · 2019: 51 · 2018: 40 · 2017: 2
- FWCI
- 33.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- American Journal of Nephrology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- canagliflozin, SGLT2 inhibitors, type 2 diabetes, diabetic nephropathy, albuminuria, end-stage renal disease, cardiovascular outcomes, renal outcomes, CREDENCE trial, trial design, baseline characteristics
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Adult, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.